ClinicalTrials.gg
Not yet recruitingNCT07308093VR PNF RPT PDUpdated Nov 5, 2026

Comparative Effects of Virtual Reality and Proprioceptive Neuromuscular Facilitation in Patients With Parkinson's Disease

An interventional study of Intervention 1 and artificial intelligence in Parkinson Disease, sponsored by Lahore University of Biological and Applied Sciences. Not yet recruiting at 1 site in Pakistan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Lahore University of Biological and Applied Sciences · Not applicable, Interventional, and Treatment

How we know

Updated Nov 5, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Parkinson Disease with a site in Pakistan — 14 open to participants now, 15 under way, none of them phase 3. Parkinson Disease · Pakistan.

Planned enrollment
26th of 30
28 · median 42
Started
2026
with 8 others
No phase
30 of 34
14 open now
Primary completion
2027-12
later than 14 of 14 live
Registered
25th of 34
by date
Lead sponsor
3 of 34
Lahore University of Biological and Applied Sciences

Among the 34 studies in Parkinson Disease with a site in Pakistan, this one is the 26th largest by planned enrollment of the 30 interventional ones that give a count, is one of 9 that started in 2026, is one of 30 with no phase, reaches primary completion later than 14 of the 14 other live ones, and was the 25th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

14 of the 34 studies in Parkinson Disease with a site in Pakistan are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease with a site in Pakistan, or all of them as a file.
02

Study summary

Parkinson's Disease is a chronic neurodegenerative disorder marked by the progressive loss of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein (Lewy bodies).It impacts both motor and non-motor systems, with growing global prevalence-affecting 7-10 million people, mostly men over 60 years-due to increasing life expectancy and demographic shifts.

PD shows motor symptoms like tremors and bradykinesia, along with non-motor issues like depression, REM sleep disorder, and cognitive decline. Diagnosis is often delayed due to subtle early signs like constipation or shoulder pain and atypical cases lacking classical tremors.

VR offers immersive, task-specific therapy that enhances motor learning and neuroplasticity in a safe, engaging environment. By integrating sensory feedback and real-time motion tracking, VR reduces tremors, promotes cortical reorganization (notably in the sensorimotor cortex and cerebellum), and increases rehabilitation motivation through gamified experiences.

PNF is a hands-on therapy using tactile, auditory, and proprioceptive cues to improve coordination, strength, and movement patterns. Especially useful in Parkinson's rehabilitation, PNF targets rigidity, bradykinesia, tremors, and postural instability by reinforcing neuromuscular coordination and improving movement execution in functional, diagonal planes.

Sensorimotor control is the dynamic integration of sensory input, motor planning, and execution, which becomes disrupted in PD due to impaired proprioception and feedback loops. Patients rely excessively on visual feedback, making movement effortful, highlighting the need for focused upper limb rehabilitation strategies.

Read the detailed description
  • Experimental: (VR+ RPT) Participants in this group received Virtual Reality (VR)-based training in addition to Routine Physical Therapy (RPT). The VR intervention was delivered using the Oculus Meta Quest 3 headset and consisted of immersive, goal-directed tasks performed three times per week for six weeks, each session lasting 30 minutes at a moderate intensity (RPE 11-13). VR tasks were designed to target specific motor impairments, including pick-and-place tasks for kinetic tremor reduction, tracing tasks to address bradykinesia, and reaching and grasping tasks to improve proprioception. Participants interacted with five virtual balls in a simulated environment, transferring them from one basket to another under therapist supervision. Alongside VR, participants also underwent Routine Physical Therapy (RPT) three times per week for six weeks, each 40-minute session consisting of a warm-up with diaphragmatic breathing, 30 minutes of stretching and strengthening for the core, hip, knee, back, and elbow extensors, and a cool-down with static stretches for major muscle groups.
  • Control: (PNF+RPT) Participants in this group received Proprioceptive Neuromuscular Facilitation (PNF) therapy in addition to Routine Physical Therapy (RPT). PNF was administered three times per week for six weeks, with each session lasting 30 minutes at a moderate intensity (RPE 11-13). Specific PNF techniques were selected for symptom management: slow reversal for kinetic tremor to improve coordinated agonist-antagonist contractions, rhythmic initiation for bradykinesia to facilitate movement initiation, and tactile input to enhance proprioception and body awareness. PNF was administered under the direct guidance of a physical therapist, with manual contact and graded resistance tailored to individual capacity. Participants also received RPT on the same schedule and with the same structure as described for the experimental group, including warm-up breathing, targeted stretching and strengthening, and cool-down static stretches.
03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • Sensorimotor Control
  • Virtual Reality Therapy
  • Proprioceptive Neuromuscular Facilitation
  • Upper Limb Rehabilitation
  • Neuroplasticity
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Idiopathic Parkinson's Disease according to Gelb's criteria
  2. Stage II-IV Hoehn \&Yahr scale
  3. Intact cognition status ( > 24)
  4. 50-80 years of age

Exclusion criteria

Exclusion Criteria:

  1. History of PD surgery
  2. Phobia of virtual gaming systems
  3. Visual anomalies
  4. Cardiovascular problems
  5. Severe dyskinesia or "on-off" fluctuations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Virtual Reality

    Participants in this group received Virtual Reality (VR)-based training in addition to Routine Physical Therapy (RPT). The VR intervention was delivered using the Oculus Meta Quest 3 headset and consisted of immersive, goal-directed tasks performed three times per week for six weeks, each session lasting 30 minutes at a moderate intensity (RPE 11-13). VR tasks were designed to target specific motor impairments, including pick-and-place tasks for kinetic tremor reduction, tracing tasks to address bradykinesia, and reaching and grasping tasks to improve proprioception. Participants interacted with five virtual balls in a simulated environment, transferring them from one basket to another under therapist supervision. Alongside VR, participants also underwent Routine Physical Therapy (RPT) three times per week for six weeks, each 40-minute session consisting of a warm-up with diaphragmatic breathing, stretching, strengthening and cool-down.

    Device: artificial intelligence

  • Active comparator
    Proprioceptive Neuromuscular Facilitation

    Participants in this group received Proprioceptive Neuromuscular Facilitation (PNF) therapy in addition to Routine Physical Therapy (RPT). PNF was administered three times per week for six weeks, with each session lasting 30 minutes at a moderate intensity (RPE 11-13). Specific PNF techniques were selected for symptom management: slow reversal for kinetic tremor to improve coordinated agonist-antagonist contractions, rhythmic initiation for bradykinesia to facilitate movement initiation, and tactile input to enhance proprioception and body awareness. PNF was administered under the direct guidance of a physical therapist, with manual contact and graded resistance tailored to individual capacity. Participants also received RPT on the same schedule and with the same structure as described for the experimental group, including warm-up breathing, targeted stretching and strengthening, and cool-down static stretches.

    Other: Intervention 1

Interventions

  • OtherIntervention 1

    Participants in the control group received Proprioceptive Neuromuscular Facilitation (PNF) therapy three times per week for a total duration of six weeks. Each session lasted approximately 30 minutes and was conducted at a moderate intensity, corresponding to an RPE of 11-13 on the Borg scale. For kinetic tremors, the slow reversal technique was applied. For bradykinesia, the rhythmic initiation technique was used. And to enhance proprioception, tactile input was provided through manual contact, resistance, and stretch applied by the therapist at key points of the movement pattern.

    Also known as: Proprioceptive Neuromuscular Facilitation

  • Deviceartificial intelligence

    Participants in the experimental group underwent Virtual Reality (VR) training three times per week for a total of six weeks. Each session lasted approximately 30 minutes and was conducted at a moderate intensity, defined by the repetition of VR tasks five times per session. The intervention was delivered using the Oculus Meta Quest 2 head-mounted display, providing an immersive and interactive environment under the close supervision of a licensed physical therapist. The central activity involved 2 modules. Ball Shifting Module picking and placing five virtual balls within the simulated environment and transferring them from one basket to another. Cube Navigation Module, in this task, users guide a virtual cube through highlighted cells or routes using deliberate movements, requiring precise hand positioning and controlled movement paths.

06

What researchers measure

Primary outcomes

  1. Kinetic Tremors

    Kinetic Tremors It is going to be measured by: Fahn-Tolosa-Marin tremor rating scale with internal consistency of Cronbach's α = 0.90. FTMTRS - Kinetic Tremor Section Rate the severity of tremor during each task using the following scale: 1. Writing: \_\_\_\_\_\_\_ 2. Drawing (Archimedes spiral): \_\_\_\_\_\_\_ 3. Pouring water: \_\_\_\_\_\_\_ 4. Drinking from a cup: \_\_\_\_\_\_\_ • Total Kinetic Tremor Score: \_\_\_\_\_\_\_/16 (0 = No tremor, 1 = Mild, intermittent, 2 = Moderate, intermittent or mild, continuous, 3 = Marked, intermittent or moderate, continuous, 4 = Severe, continuous)

    Time frame: 6 weeks

  2. Bradykinesia

    It is going to be measured by: MDS-UPDRS Part III with internal consistency of Cronbach's α: 0.90-0.93. MDS-UPDRS Part III - Bradykinesia Items (3.4-3.6) Rate each movement on a scale from 0 (normal) to 4 (severe): 1. 3.4 L\&R Finger Tapping: \_\_\_\_\_\_\_ 2. 3.5 L\&R Hand Movements (open/close hands): \_\_\_\_\_\_\_ 3. 3.6 L\&R Pronation-Supination of Hands: \_\_\_\_\_\_\_ • Total Bradykinesia Score (3.4-3.6): \_\_\_\_\_\_\_/24

    Time frame: 6 weeks

  3. Proprioception

    •It is going to be measured by: Fugl Meyer UE Proprioception subscale with internal consistency of Cronbach's α: at 0.94-0.98. Scoring: 0 = Only a few degrees (less than 10° in shoulder) 1. = Decreased 2. = Normal Shoulder Movement 0 1 2 Flexion (0°-180°) ☐ ☐ ☐ Abduction (0°-90°) ☐ ☐ ☐ External Rotation ☐ ☐ ☐ Internal Rotation ☐ ☐ ☐ Elbow Movement 0 1 2 Flexion ☐ ☐ ☐ Extension ☐ ☐ ☐ Forearm Movement 0 1 2 Pronation ☐ ☐ ☐ Supination ☐ ☐ ☐ Wrist Movement 0 1 2 Flexion ☐ ☐ ☐ Extension ☐ ☐ ☐ Fingers Movement 0 1 2 Flexion ☐ ☐ ☐ Extension ☐ ☐ ☐

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — After the publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: June 2026- October 2026

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 13 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: start Jan 2026 → Nov 2026, primary completion Jul 2026 → Dec 2027 and completion Jul 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartEst.
Nov 15, 2026was Jan 2026
Primary completionEst.
Dec 2027was Jul 2026
CompletionEst.
Dec 31, 2027was Jul 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 31, 2026→Nov 15, 2026
Nov 5, 2026
Primary completion
Jul 31, 2026→Dec 2027
Nov 5, 2026
Study completion
Jul 31, 2026→Dec 31, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Start date Jan 31, 2026→Nov 15, 2026
    Primary completion Jul 31, 2026→Dec 2027
    Study completion Jul 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07308093
Lead sponsor
Lahore University of Biological and Applied Sciences
Responsible party
Prof. Dr. Shoaib Waqas (Dean-0Study Chair, Lahore University of Biological and Applied Sciences) — Principal investigator
First posted
Dec 29, 2025
Start date
Nov 15, 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Shoaib Waqas, PhD
Contact
shoaib.waqas@ubas.edu.pk
03024552109
Shoaib Waqas, PhD
study chair · Lahore University of Biological and Applied Sciences
Javeria Younas, DPT
principal investigator · Lahore College of Physical Therapy
Fatima Rehan, DPT
principal investigator · Lahore College of Physical Therapy
Laiba Dhillon, DPT
principal investigator · Lahore College of Physical Therapy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion